# US 2020/0347046 A1 · Nitrogen-containing 6-membered cyclic compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0347046 A1
- Document ID: US20200347046A1
- Status: Published application
- Kind: A1
- Application number: 16/333,510
- Filed: 2018-12-25
- Published: 2020-11-05
- Earliest claimed: 2017-12-25
- Assignees: Asahi Kasei Pharma Corporation
- Applicants: Asahi Kasei Pharma Corporation
- Inventors: Daisuke SHIKANAI; Noriko ISHIGURO; Osamu OMORI
- Web page: https://patentgrep.com/patent/US20200347046A1

## CPC

- A61K 31/5395: having two or more nitrogen atoms in the same ring, e.g. oxadiazines
- C07D 417/14: containing three or more hetero rings
- A61K 31/549: having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A novel compound represented by the following general formula (1), or a salt thereof, which has a superior EP4 receptor agonist activity, and a medicament containing the compound or a salt thereof as an active ingredient, which can be used for promotion of osteogenesis, therapeutic treatment and/or promotion of healing of fracture and the like.

## Claims

### Claim at position 1

-12. (canceled)

### Claim 13

The compound mentioned below, or a salt thereof;

### Claim 14

The compound mentioned below, or a salt thereof;

### Claim 15

The compound mentioned below, or a salt thereof;

### Claim 16

The compound mentioned below, or a salt thereof;

### Claim 17

The compound mentioned below, or a salt thereof;

### Claim 18

The compound mentioned below, or a salt thereof;

### Claim 19

The compound mentioned below, or a salt thereof;

### Claim 20

(canceled)

### Claim 21 (depends on 13, 14, 15, 16, 17, 18, 19)

A medicament containing the compound according to any one of claims 13 to 19 or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim 22 (depends on 21)

The medicament according to claim 21, which is for therapeutic treatment and/or promotion of healing of fracture.

### Claim 23 (depends on 21)

The medicament according to claim 21, which is for promotion of bone union in spinal fusion surgeries
